|
Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
|
19 December 2016 |
|
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
|
16 December 2016 |
|
Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
|
12 December 2016 |
|
Novartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to work
|
05 December 2016 |
|
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
|
21 November 2016 |
|
Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study
|
16 November 2016 |
|
Novartis wins two prestigious Prix Galien Foundation Awards
|
31 October 2016 |
|
Novartis delivered solid third quarter
|
25 October 2016 |
|
Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
|
04 October 2016 |
|
Sandoz invites young entrepreneurs to enter #SandozHACk, a global competition to help solve healthcare access challenges
|
28 September 2016 |